Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05UJF
|
|||
| Former ID |
DIB003135
|
|||
| Drug Name |
PBSVax
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
Profectus biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Profectus biosciences. | |||
| REF 2 | ClinicalTrials.gov (NCT01578889) Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.